Seelos Therapeutics, Inc. (SEELQ)

Seelos Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	4.09	-37.88	-73.53	-66.05	-19.1	-51.26
Depreciation & Amortization	0.06	0.06	0.05	-	-	-
Other Amortization	-	-	-	1.58	0.15	-
Asset Writedown & Restructuring Costs	-	-	1.3	5.64	0.19	3
Stock-Based Compensation	3.77	3.99	5.07	8.35	2.17	0.46
Other Operating Activities	-33.95	-2.49	2.73	2.89	0.22	21.63
Change in Accounts Payable	9.25	12.78	1.93	-0.19	1.09	-1.42
Change in Other Net Operating Assets	3.51	-0.36	0.85	-1.21	-5.64	8.29
Operating Cash Flow	-13.27	-23.91	-61.6	-49	-20.91	-19.31
Long-Term Debt Issued	-	-	-	-	0.15	-
Long-Term Debt Repaid	-	-7.64	-1.89	-13.55	-	-
Net Debt Issued (Repaid)	-5.54	-7.64	-1.89	-13.55	0.15	-
Issuance of Common Stock	13.27	20.21	0.56	125.62	26.17	13
Repurchase of Common Stock	-	-1.2	-	-	-	-
Other Financing Activities	-	-	-0.27	-	-	16.52
Financing Cash Flow	7.73	11.38	-1.6	112.07	26.31	29.52
Net Cash Flow	-5.55	-12.54	-63.2	63.07	5.4	10.22
Cash Interest Paid	0.41	0.51	0.01	0.01	0.01	0.02
Levered Free Cash Flow	-34.28	-5.11	-35.6	-30.29	-16.29	-9.26
Unlevered Free Cash Flow	-34.21	-5.07	-35.59	-30.87	-16.33	-9.25
Change in Working Capital	12.76	12.42	2.78	-1.41	-4.55	6.86

Updated Aug 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.